Neutrophil extracellular traps predict sensitivity to neoadjuvant chemotherapy combined with immunotherapy in locally advanced gastric cancer

Table 3 Logistic regression analysis for predictors of pathological complete response in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy combined with immunotherapy

Variables	Univariate analyses		Multivariate analyses
	HR (95%CI)	P value	HR (95%CI)	P value
Sex
Female	1 [Reference]	NA
Male	1.50 (0.27-8.38)	0.644
Age
< 65	1 [Reference]	NA
≥ 65	2.12 (0.34-13.13)	0.421
Tumor location
Lower third	1 [Reference]	NA
Middle third	5.20 (0.71-37.90)	0.104
Upper third	4.80 (0.40-58.01)	0.217
cT stage
cT3	1 [Reference]	NA
cT4a	1.00 (0.05-19.96)	1.000
cT4b	0.40 (0.04-4.24)	0.447
cN stage
cN1	1 [Reference]	NA
cN2	0.00 (0.00-Inf)	0.995
cN3	0.00 (0.00-Inf)	0.995
PD-L1 scores	0.87 (0.77-0.99)	0.028	0.85 (0.73-0.99)	0.041
Tumor grade
G1-2	1 [Reference]	NA
G3	1.50 (0.27-8.38)	0.644
Immunotherapy
Nivolumab	1 [Reference]	NA
Tislelizumab	1.82 (0.27-12.17)	0.538
Others	1.09 (0.09-13.78)	0.946
NLR
High	1 [Reference]	NA
Low	0.33 (0.03-3.26)	0.345
Pre-NACI NET
High	1 [Reference]	NA	1 [Reference]	NA
Low	0.10 (0.01-0.97)	0.047	0.07 (0.00-0.96)	0.047

NACI: Neoadjuvant chemotherapy combined with immunotherapy; HR: Hazard ratio; CI: Confidence interval; NET: Neutrophil extracellular trap; NLR: Neutrophil-to-lymphocyte ratio.